Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Eli Lilly executive Eric Dozier, EVP and Chief People Officer, reported several equity transactions dated February 1, 2026. A block of 2,858 restricted stock units converted into the same number of Eli Lilly common shares at $0 per share, increasing his direct holdings. On the same date, a disposition coded “F” covered 1,272.992 common shares at $1,037.15 per share, leaving Dozier with 11,423.918 common shares held directly. He also reports an additional 376.93 common shares held indirectly through a 401(k) account.
Lilly Endowment, Inc., an Indiana not‑for‑profit private foundation, reported its ownership of 92,190,516 shares of Eli Lilly and Company common stock as of December 31, 2025. This stake represents 9.8% of Eli Lilly’s outstanding common stock, based on 945,383,757 shares outstanding as of October 27, 2025, as referenced from Eli Lilly’s Form 10‑Q for the period ended September 30, 2025.
The endowment has sole voting power and sole dispositive power over all 92,190,516 shares and reports no shared voting or shared dispositive power. None of these shares are reported as being beneficially owned through rights to acquire additional shares; they reflect existing common shares held by the endowment.
Eli Lilly and Company director Gabrielle Sulzberger reported a small acquisition of company stock as part of board compensation. On January 20, 2026, she acquired 4.762 shares of Eli Lilly common stock at a price of $1,041.29 per share, bringing her directly held beneficial ownership to 2,961.436 shares.
According to the filing, these shares were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They are credited as stock units and are scheduled to be settled in actual shares of common stock after her separation from service as a director. The transaction reflects routine director compensation rather than an open-market purchase or sale.
Eli Lilly and Company director Juan R. Luciano reported an acquisition of company common stock through the deferral of board compensation. On January 20, 2026, he acquired 15.286 shares of Eli Lilly common stock at a price of $1,041.29 per share, recorded as an "A" transaction. After this transaction, he beneficially owned 16,756.656 shares of Eli Lilly common stock in direct ownership.
According to the disclosure, Mr. Luciano elected to defer his cash compensation into stock units under the Lilly Directors' Deferral Plan. These deferred stock units will be settled in shares of common stock after he separates from service as a director, meaning the award is part of his director compensation structure rather than an open-market purchase.
Eli Lilly & Co. director J. Erik Fyrwald reported an acquisition of company common stock through a compensation deferral arrangement. On January 20, 2026, he acquired 9.523 shares of Eli Lilly common stock at $1,041.29 per share, increasing his directly held beneficial ownership to 75,110.75 shares.
According to the disclosure, these shares were not received as immediate cash pay but were deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan. They will be settled in shares of common stock after Fyrwald separates from service as a director, reflecting standard equity-based director compensation rather than an open-market trade.
Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.924 shares of Eli Lilly common stock on January 20, 2026. According to the filing, this amount represents fees that he elected to defer as stock units under the Lilly Directors' Deferral Plan, instead of taking cash, and these units will be settled in Eli Lilly common shares after he leaves board service.
Following this transaction, Alvarez directly beneficially owned 55,479.642 shares of Eli Lilly common stock. The filing also reports an additional 758 shares held indirectly through a trust, for which he disclaims beneficial ownership except to the extent of his economic interest.
Eli Lilly and Company filed a Schedule 13D disclosing an 11.9% ownership stake in Aktis Oncology, Inc. following Aktis’s initial public offering. Lilly reports beneficial ownership of 6,344,114 shares of Aktis common stock, based on 53,296,950 shares outstanding after the IPO and full exercise of the underwriters’ option.
The stake comes from the conversion of preferred stock acquired for $12.0 million into 788,559 common shares at the IPO closing and the purchase of 5,555,555 shares in the IPO at $18.00 per share for about $100.0 million in cash. Lilly states it acquired the position for investment purposes, may buy or sell shares over time, and is party to an Investors’ Rights Agreement providing registration rights, as well as a 180‑day IPO lock-up restricting sales through mid‑2026.
Eli Lilly & Co filed an initial ownership report showing a significant equity position in Aktis Oncology, Inc. (AKTS). As of 01/12/2026, Eli Lilly beneficially owned 6,344,114 shares of Aktis Oncology common stock, reported as a direct holding and establishing it as a 10% owner of the company. The filing does not list any derivative securities, so the disclosed stake consists solely of common shares. This type of report is a standard regulatory disclosure of a large shareholder’s position.
Lilly Endowment Inc., a more than 10% owner of Eli Lilly and Company (LLY), reported a series of open-market sales of Eli Lilly common stock on January 7, 2026. The Form 4 shows multiple block sales at weighted average prices generally between $1,085.108 and $1,116.686 per share, with each price reflecting numerous individual trades within narrow ranges as detailed in the footnotes. After these transactions, Lilly Endowment Inc. beneficially owned 91,896,978 shares of Eli Lilly common stock held directly.
Eli Lilly and Company executive Carole Ho, EVP & President of Lilly Neuroscience, reported her beneficial ownership of derivative equity awards. She holds restricted stock units covering 2,741.306 shares of Eli Lilly common stock. These RSUs vest in three installments: 904.631 units on December 1, 2026, 932.044 units on December 1, 2027, and 904.631 units on December 1, 2028. Each restricted stock unit represents a contingent right to receive one share of Eli Lilly common stock, aligning a portion of her compensation with the company’s share performance over time.